Engineering the Medicines of Tomorrow - MorphoSys AG · This presentation includes forward-looking...

Engineering the Medicines of TomorrowCompany Update

AUGUST 2017

This presentation includes forward-looking statements.

Actual results could differ materially from those included in

the forward-looking statements due to various risk factors

and uncertainties including changes in business, economic competitive

conditions, regulatory reforms, foreign exchange rate fluctuations

and the availability of financing. These and other risks and

uncertainties are detailed in the

Company’s Annual Report.

© MorphoSys AG, Company Update – August 2017 2

Investment Highlights

© MorphoSys AG, Company Update – August 2017

Collaborations

from academia to

top tier pharma

Over 100 programs

ongoing, 29 in the clinic

Lucrative milestone

& royalty potential

Novel antibody and

peptide formats

Strong balance sheet

Leading Antibody Platform

First Products Nearing Market

Successful Partnering Track Record

Innovative Technologies

Well-Capitalized

3

PARTNERED DISCOVERY

Maximising utilization of the technology

Lucrative source of revenue from license fees

and royalties

Strategy


PROPRIETARY DEVELOPMENT

Focus on oncology/inflammation

Selective co-development programs

Retained rights translate into higher revenue

potential

TECHNOLOGY PLATFORMS: HuCAL & Ylanthia; Lanthipeptides; Novel Targets

Developing Treatments for Patients Suffering from Serious Diseases

4

Our Clinical Pipeline29 Product Candidates in Clinical Development


Partnered Discovery Programs

Proprietary Development Programs

5

PROGRAM PARTNER TARGET DISEASE AREA PHASE 1 PHASE 2 PHASE 3 LAUNCH

Guselkumab (CNTO1959) Janssen IL23p19 Psoriasis

Gantenerumab Roche Amyloid-ß Alzheimer’s disease

MOR208 - CD19 DLBCL, CLL/SLL

Anetumab Ravtansine (BAY94-9343) Bayer Mesothelin (ADC) Solid tumors

BHQ880 Novartis DKK-1 Multiple myeloma

Bimagrumab (BYM338) Novartis ActRIIB Musculoskeletal diseases

BPS804 Mereo/Novartis Sclerostin Brittle bone syndrome

CNTO3157 Janssen - Inflammation

CNTO6785 Janssen - Inflammation

Elgemtumab (LJM716) Novartis HER3 Cancer

MOR103/GSK3196165* GSK GM-CSF Inflammation

MOR202 - CD38 Multiple myeloma

Tesidolumab (LFG316) Novartis C5 Eye diseases

Utomilumab (PF-05082566) Pfizer 4-1BB Cancer

VAY736 Novartis BAFF-R Inflammation

Xentuzumab (BI-836845) BI IGF-1 Solid tumors

BAY1093884 Bayer TFPI Hemophilia

MOR106 Galapagos IL-17C Inflammation

MOR107 (LP2-3) Lanthio Pharma AT2-R Not disclosed

MOR209/ES414 Aptevo PSMA/CD3 Prostate cancer

NOV–7 Novartis - Eye diseases

NOV–8 Novartis - Inflammation

NOV-9 Novartis - Diabetic eye diseases

NOV-10 Novartis - Cancer

NOV-11 Novartis - Blood disorders

NOV-12 Novartis - Prevention of thrombosis

NOV-13 Novartis - Cancer

NOV-14 Novartis - Asthma

Vantictumab (OMP-18R5) OncoMed Fzd 7 Solid tumors

13

13

2

* MOR103/GSK3196165 is out-licensed to GSK

Proprietary Development: MOR208An Fc-Enhanced Anti-CD19 Antibody to Treat Blood Cancer


KEY FEATURES

CD19 is a crucial survival molecule on the

surface of B-cells

MOR208 shows excellent drug-like properties

− Fc modification enhances target cell killing

− Straight-forward manufacturing

− 15 day half-life

CLINICAL

MOR208 has a very good safety profile

− Opportunity to be used with multiple

combination partners

− Supports use in frail patients

Encouraging clinical efficacy guides further

development addressing unmet needs in B-cell

malignancies

6

INDICATION 2016 2017 2018

MOR208: Clinical Development Plan


*R/R = relapsed/refractory

Non-Hodgkin’s Lymphoma(NHL)

MOR208 monotherapy in

R/R* NHL (12mg/kg); N=92

Diffuse Large B-cell Lymphoma (DLBCL)

Chronic LymphocyticLeukemia(CLL)

MOR208 (9mg/kg) + lenalidomide; in CLL

MOR208 + ibrutinib in ibrutinib-resistant CLL

Proprietary program trial IIT: Investigator-initiated trial, John Byrd, Ohio State University

Lenalidomide + MOR208 (12mg/kg) in R/R* DLBCL; N=80L-MIND

Bendamustine + MOR208 (12mg/kg) vs. bendamustine + rituximab in

R/R* DLBCL; N~330; pivotal phase 3 part started in 2017B-MIND

MOR208 (12mg/kg) + idelalisib in R/R* CLL BTKi-failures

MOR208 (12mg/kg) + venetoclax in R/R* CLL BTKi-failuresCOSMOS

Anticipated Interim Reporting

7

Exploiting Synergies Between MOR208 and Approved Anti-Cancer Agents

27%

0

20

40

60

80

100

MOR208 Shows Promising Clinical Data


iNHL

(12mg/kg)

n=45

DLBCL

(12mg/kg)

n=35

44%

18%

11%

Best

Overa

ll R

esp

onse

[%]

ORR 26% ORR 29%

14%

60%

20%

6%

Complete response

Partial response

Progressive Disease/Not evaluable

Stable disease

Response Rates Deepened in Combination Study in Diffuse Large B-Cell Lymphoma (DLBCL)

PHASE 2 STUDY (MONOTHERAPY) IN

R/R NON-HODGKIN’S LYMPHOMA (NHL)

8

PHASE 2 L-MIND STUDY

(IN COMBINATION WITH LENALIDOMIDE) IN R/R DLBCL*

0

20

40

60

80

100

Best

Overa

ll R

esp

onse

[%]

ORR 56%

12%(n=4)

32%(n=11)

24%(n=8)

32%(n=11)

n=34

R/R = relapsed/refractory

iNHL = indolent non-Hodgkin‘s lymphoma

*From ongoing phase 2 trial: Kami Maddocks, at ASCO, June 5, 2017: Abstract #7514

Proprietary Development: MOR202A Differentiated Anti-CD38 Antibody to Treat Multiple Myeloma


KEY FEATURES

Targets a unique epitope on CD38

ADCC & ADCP cell-killing mechanisms

Low NK-cell depletion, which may translate into

longer duration of response

CLINICAL*

Very low rate of infusion-related reactions

Short infusion time

Enduring & deepening clinical responses:

− Responses ongoing in 65% of patients

− Longest time on study with ongoing

response: >19 months

Potential in other oncology indications and auto-

immune diseases

ADCC: Antibody-Dependent Cell-Mediated Cytotoxicity

ADCP: Antibody-Dependent Cell-Mediated Phagocytosis

ADCC

ADCP

* From ongoing phase 1/2a trial: Raab et al., Poster Presentation at ASCO, June 5, 2017: Abstract #8024

EFFICACY

MOR202 Shows Promising Clinical Data*Clear Differentiation vs. Other CD38 Antibodies

*From ongoing phase 1/2a trial: Raab et al., Poster Presentation at ASCO, June 5, 2017: Abstract #8024


SAFETY

MOR202 appears to be well tolerated with a very low incidence of infusion related reactions, mainly

limited to the first infusion (IRR: 6%, grade 1 and 2)

CONVENIENCE

Short & predictable infusion time of 2 hours at highest doses

MOR202/DEXMOR202/

POMALIDOMIDE/DEX

MOR202/

LENALIDOMIDE/DEX

Number of patients 18 13 17

Median prior therapies 5 4 3

Overall response rate

(ORR)

28% 46% 71%

Median progression free

survival (PFS)

4.7 months 17.5 months not yet reached

Patients still on study 0 8 9

DEX = Dexamethasone

TremfyaTM (Guselkumab): FDA Granted ApprovalFirst Approved Partnered Program Available since End of July 2017


DRUG

First in class IL-23-specific antibody

Partnered discovery project with Janssen

KEY FEATURES

Potential to provide unique value to patients: high levels of

complete or almost complete skin clearance in phase 3 studies

Less intensive dosing regimens vs. anti-IL-17 class

Specificity for IL-23 spares Th1 pathway targeted by STELARA®,

which binds IL-12 & IL-23

LATEST UPDATES FROM JANSSEN

Trade name TremfyaTM

Available to patients in the US

Phase 3 study head-to-head vs. Cosentyx® started

Phase 3 study in psoriatic arthritis (PsA) to start enrolment soon

New phase 3 studies in psoriatic arthritis & Crohn’s announced

11

STELARA® is a registered trademarks of Johnson & Johnson; TremfyaTM is a trademark by Janssen Biotech; Cosentyx® is a registered trademark of Novartis AG

VOYAGE 1: PHASE 3 PSORIASIS STUDY RESULTS

GuselkumabCompelling Efficacy in Phase 3 Trial


Data courtesy of

Week 48

P<0.001 vs. ADAWeek 24

P<0.001 vs. ADAWeek 16

P<0.001 vs. ADA

Adalimumab (Humira®):

80 mg at week 0, followed

by 40 mg at week 1 and q2w

thereafter through week 48

Patients achieving skin improvements - measured by Psoriasis Area and

Severity Index (PASI 90) through Week 48 (in %)

Guselkumab:

100 mg at weeks 0, 4, 12

and q8w thereafter through

week 48

Guselkumab (n=329) Placebo Guselkumab (n=174) Adalimumab (n=334)

12

Humira® is a registered trademark of AbbVie Biotechnology Ltd.

Selected Other Clinical AssetsTargeting Multiple Diseases with High Unmet Medical Need


COMPOUND PARTNER TARGET DISEASE AREA STATUS

Gantenerumab Roche Amyloid-β Alzheimer’s disease Phase 3

Utomilumab

(PF–05082566)Pfizer 4-1BB Cancer Phase 2

MOR103/GSK3196165 GSK GM-CSFRheumatoid arthritis

Hand osteoarthritisPhase 2

BI-836845 BI IGF-1 Solid tumors Phase 2

Bimagrumab Novartis ActRIIB

Hip fracture surgery

Sarcopenia

Type 2 diabetes

Phase 2

Elgemtumab

(LJM716)Novartis HER3 Cancer Phase 2

MOR106 Galapagos IL-17C Atopic dermatitis Phase 1

13



Expected Pipeline NewsflowUp to 30 Clinical Data Points Expected until Year-end 2017*


PHASE 1 PHASE 2 PHASE 3 LAUNCH

Anetumab RavtansineCancer

BAY-1093884Bleeding disorders

Anetumab RavtansineMesothelioma (MPM)

Elgemtumab (LJM716)Esophageal cancer

(+ BYL716)

GuselkumabPsoriasis (VOYAGE 2)

GuselkumabPsoriasis

Elgemtumab (LJM716)Breast cancer

(+ BYL716/trastuzumab)

Elgemtumab (LJM716)Breast/gastric cancer

GuselkumabActive psoriatic arthritis

(PsA)

MOR103/GSK3196165Osteoarthritis

GuselkumabPsoriasis (NAVIGATE)

GantenerumabAlzheimer’s disease

(sc, impact of speed)

Gantenerumab Alzheimer’s disease (sc)

MOR103/GSK3196165Rheumatiod arthritis


(Japan)

GuselkumabModerate to severe plaque

psoriasis (POLARIS)

MOR106Atopic dermatitis

MOR107Not disclosed

(trial ongoing)


MOR202Multiple Myeloma

(trial ongoing)

GuselkumabSevere plaque psoriasis

NOV-7Eye diseases

Tesidolumab

(LFG316) Kidney Transplantation

MOR208DLBCL (+ lenalidomide)

(trial ongoing)

MOR208CLL (+ lenalidomide)

(IIT)

Utomilumab

(PF-05082566)Solid tumors (+ MK-3475)

Utomilumab

(PF-05082566)NHL/solid tumors

(+ rituximab)

Tarextumab

(OMP-59R5)Small cell lung cancer

Tesidolumab (LFG316) Geographic atrophy

(+ CLG561)

Utomilumab

(PF-05082566)

Solid tumors

(+ mogamulizumab)

Vantictumab

(OMP-18R5)Pancreatic cancer

Tesidolumab (LFG316) Paroxysmal nocturnal

hemoglobinuria

Tesidolumab (LFG316) Panuveitis

Vantictumab

(OMP-18R5)Lung Cancer (NSCLC)

Vantictumab

(OMP-18R5)Breast cancer

VAY736Rheumatoid arthritis

Xentuzumab

(BI-836845)Prostate cancer

(+ enzalutamide)

Xentuzumab

(BI-836845)Multiple cancer types

(EGFR mutant NSCLC)

Xentuzumab

(BI-836845)Breast cancer



* Anticipated data readouts and/or primary completion dates,

according to clinicaltrials.gov and/or MorphoSys‘s own estimates

Positive data readout

Negative data readout

Financial Guidance 2017* Re-confirmation

*As stated before, revenues from potential future collaborations and/or licensing partnerships, nor effects from potential in-licensing or co-development

deals for new development candidates are not included. Included is a milestone payment for the TremfyaTM approval. Royalties for TremfyaTM cannot be

accurately projected shortly after the approval, guidance will be reviewed as soon as the revenue uptake allows for reliable projections for FY 2017.

15

IN € MILLION FY 2016 Q1-Q2 2017 GUIDANCE 2017

49.7 23.6 46 to 51

78.5 37.9 85 to 95

-59.9 -30.3 -75 to -85

359.5 334.8

Group Revenues

Proprietary R&D Expenses

(incl. Technology Development)

EBIT

Cash, cash equivalents & marketable

securities as well as other short-term

and long-term financial assets

(end of reporting period)


TODAY

Our Future


OUR FUTURE

First product candidate in

registration in the US and Europe

Maturing clinical pipeline

set to deliver a lot of data

Powerful technology platform

delivering differentiated

drug candidates

Marketed products delivering lucrative

royalty stream

Revenues fuel pipeline and R&D engine

First commercial footprint established

16


Appendix

17

Clinical ProgramsOngoing Clinical Trials (1)


PROGRAM PARTNER TARGET INDICATION PHASE 1 PHASE 2 PHASE 3

Guselkumab Janssen/J&J IL23p19 Plaque psoriasis (VOYAGE 1)

(CNTO1959) Plaque psoriasis (VOYAGE 2)

Plaque psoriasis (NAVIGATE)

Pustular/Erythrodermic psoriasis

Plaque psoriasis

Plaque psoriasis (POLARIS)

Palmoplantar pustulosis

Moderate to severe plaque psoriasis (efficacy & safety)

Moderate to severe plaque psoriasis (ECLIPSE)

Psoriatic arthritis (PsA)

Gantenerumab Roche Amyloid-ß Mild Alzheimer's disease (Marguerite RoAD)

Prodromal Alzheimer's disease

Genetically predisposed for Alzheimer's disease (DIAN)

Safety, tolerability and pharmacokinetics (sc)

Pain, tolerability, safety and pharmacokinetics (sc)

Bioavailability (sc)

MOR208 - CD19 Diffuse large B cell lymphoma (DLBCL) (B-MIND)

Chronic lymphocytic leukemia (CLL) or small lymphocytic

lymphoma (SLL) (COSMOS)

Diffuse large B cell lymphoma (DLBCL) (L-MIND)

Chronic lymphocytic leukemia (CLL) (IIT study)

Anetumab Ravtansine Bayer Mesothelin Mesothelioma (MPM)

(BAY94-9343) Cancer multi-indications

BHQ880 Novartis DKK-1 Multiple myeloma (MM) (renal insufficiency)

Smoldering multiple myeloma

Bimagrumab Novartis ActRIIB Muscular atrophy hip fracture surgery

(BYM338) Sarcopenia (dose-ranging)

Sarcopenia (withdrawal extension study)

Type 2 diabetes

BPS804 Mereo/Novartis Sclerostin Osteoporosis

Hypophosphatasia (HPP)

Brittle bone disease

Brittle bone disease (Type I, III, IV) (ASTEROID)

Brittle bone disease (Type I, III, IV) (METEOROID)

CNTO3157 Janssen/J&J Asthma

Safety and pharmacokinetic

CNTO6785 Janssen/J&J Chronic obstructive pulmonary disease (COPD)

Rheumatoid arthritis (RA)

18

Partnered Discovery Programs MOR Proprietary Development Programs



* MOR103/GSK3196165 is fully outlicensed to GSK


Elgemtumab Novartis HER3 ESCC (combo with BYL719)

(LJM716) HER2+ cancer (combo with BYL719 & trastuzumab)

HER2+ cancer (combo with trastuzumab)

MOR103/GSK3196165* GSK GM-CSF Rheumatoid arthritis (RA)

Rheumatoid arthritis (RA) (mechanistic study)

Hand osteoarthritis

Rheumatoid arthritis (RA) (combo with methotrexate)

MOR202 - CD38 Multiple myeloma (MM)

Tesidolumab Novartis C5 Age-related geographic atrophy

(LFG316) Geographic atrophy (combo with CLG561)

Panuveitis

Paroxysmal nocturnal hemoglobinuria

Transplant associated microangiopathy (TAM)

Renal disease patients awaiting kidney transplant

Utomilumab Pfizer 4-1BB Solid tumors (JAVELIN medley) (combo with avelumab)

(PF-05082566) Advanced Malignancies (combo with avelumab and PF-04518600)

Solid tumors, NHL (combo with rituximab)

Solid tumors (combo with pembrolizumab)

Solid tumors (combo with mogamulizumab)

Solid tumors (combo with PF04518600)

Diffuse large B cell lymphoma (DLBCL) (combo with avelumab)

VAY736 Novartis BAFF-R Pemphigus vulgaris

Primary Sjögren's syndrome

Rheumatoid arthritis (RA)

ADCC Mediated B Cell dEpletion and BAFF-R Blockade (AMBER)

Primary Sjögren's syndrome (efficacy & safety)

Xentuzumab (BI-836845) BI IGF-1 Breast cancer

Castration-resistant prostate cancer (CRPC)(combo with enzalutamide)

Solid tumors (Japan)

Solid tumors (combo with abemaciclib)

EGFR mutant non-small cell lung cancer (NSCLC)

BAY1093884 Bayer TFPI Hemophilia

MOR106 Galapagos IL-17C Atopic dermatitis

MOR107 (LP2-3) Lanthio Pharma AT2-R Not disclosed

MOR209 Aptevo PSMA/CD3 Prostate cancer

19





NOV-7 Novartis n.d. Eye disease

NOV-8 Novartis n.d. Inflammation

NOV-9 Novartis n.d. Diabetic eye disease

NOV-10 Novartis n.d. Cancer

NOV-11 Novartis n.d. Blood disorders

NOV-12 Novartis n.d. Prevention of thrombosis

NOV-13 Novartis n.d. Cancer

NOV-14 Novartis n.d. Asthma

Vantictumab Oncomed/Bayer Fzd 7 Breast cancer (combo with paclitaxel)

(OMP-18R5) Pancreatic cancer (combo with nap-paclitaxel & gemcitabine)

Non-small-cell lung carcinoma (NSCLC) (combo with docetaxel)

20


Covering Analysts


INSTITUTION CONTACT

Berenberg Klara Fernandes

Bryan Garnier TBD

Commerzbank Daniel Wendorff

Deutsche Bank Gunnar Romer

Edison Maxim Jacobs

Goldman Sachs Tim Woodward

HSBC Steve McGarry

Independent Research GmbH Bernhard Weininger

J.P. Morgan Cazenove James Gordon

Kempen & Co. Anastasia Karpova

Landesbank Baden-Württemberg Timo Kürschner

Oddo BHF Igor Kim

21

Financial Calendar 2017


DATE TITLE

March 9, 2017 Publication of year-end results 2016

May 3, 2017 Publication of first quarter interim statement 2017

May 17, 2017 Annual General Meeting 2017

August 3, 2017 Publication of half-year report 2017

November 7, 2017 Publication of third quarter interim statement 2017

www.morphosys.com

Thank You

MOR208, MOR202, MOR209/ES414, MOR106, MOR103, anetumab ravtansine, guselkumab, gantenerumab and all other product candidates mentioned here are

investigational drugs and have not been approved by the FDA or other ex-US regulatory agencies. HuCAL® , HuCAL GOLD®, HuCAL PLATINUM®, CysDisplay®, RapMAT®,

arYla®, Ylanthia®, 100 billion high potentials®, Slonomics®, Lanthio Pharma® and LanthioPep® are registered trademarks of the MorphoSys Group.

Anke Linnartz

Head of Corporate Communications & IR

Phone +49 (0)89 / 899 27-404

Fax +49 (0)89 / 899 27-5404

Email [email protected]

Date post:	18-Aug-2020
Category:	Documents
Upload:	others
View:	2 times
Download:	0 times

Engineering the Medicines of Tomorrow - MorphoSys AG · This presentation includes forward-looking...

Documents